Ifinatamab Deruxtecan (I-DXd)
Phase 2Active 3 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Mar 9, 2022 → Dec 15, 2026
NCT ID
NCT05280470About Ifinatamab Deruxtecan (I-DXd)
Ifinatamab Deruxtecan (I-DXd) is a phase 2 stage product being developed by Daiichi Sankyo for Extensive-stage Small-cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05280470. Target conditions include Extensive-stage Small-cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small-cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05280470 | Phase 2 | Active |
| NCT04145622 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer